Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753986 | 0.88 | ALOX5 (0.54) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL888871 | 0.85 | ALOX5 (0.55) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10140570 | 0.84 | ALOX5 (0.50) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8911009 | 0.84 | ALOX5 (0.50) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19334127 | 0.79 | ALOX5 (0.46) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13179223 | 0.79 | ALOX5 (0.46) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13083671 | 0.79 | ALOX5 (0.54) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16919015 | 0.78 | ALOX5 (0.50) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1696295 | 0.78 | ALOX5 (0.50) | ALOX5PKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10069422 | 0.78 | ALOX5 (0.56) | ALOX5PKMSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8927709-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALOX5 2512/4885PKM 954/4885SLC6A2 4023/4885 |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | ALOX5 1579/4885PKM 2520/4885SLC6A2 3213/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALOX5 1909/4885PKM 2497/4885SLC6A2 2574/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALOX5 2512/4885PKM 954/4885SLC6A2 4023/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ALOX5 2012/4885PKM 620/4885SLC6A2 3696/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALOX5 1909/4885PKM 2497/4885SLC6A2 2574/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | ALOX5 2504/4885PKM 2088/4885SLC6A2 3543/4885 |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALOX5 1909/4885PKM 2497/4885SLC6A2 2574/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | ALOX5 1379/4885PKM 2410/4885SLC6A2 2606/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | ALOX5 1379/4885PKM 2410/4885SLC6A2 2606/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | ALOX5 1379/4885PKM 2410/4885SLC6A2 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.